Literature DB >> 19535212

Amlodipine toxicity in children less than 6 years of age: a dose-response analysis using national poison data system data.

Blaine E Benson1, Daniel A Spyker, William G Troutman, William A Watson, Ludmila N Bakhireva.   

Abstract

BACKGROUND: Amlodipine is a long-acting calcium channel blocker capable of producing hypotension and dysrhythmia in overdose. The toxic doses of amlodipine in children are unclear.
OBJECTIVES: The purposes of this study were to describe amlodipine poisoning in children and to determine whether a dose-response relationship could be detected in this population using standardized call data from United States (US) poison centers. PATIENTS AND METHODS: 1251 amlodipine-only ingestions in children < 6 years of age were reviewed. Cases with doses coded as "Exact" or "Estimated" and with dose, age, and medical outcome were analyzed (n = 678). Ingestions reported as a "taste or lick" (n = 53) were included as a dose of 1/10 of the dosage form involved. A clinically important response was defined as bradycardia, hypotension, dysrhythmia, conduction disturbance, or hyperglycemia. The risk of such responses was examined over four dosage intervals (< 2.5 mg, 2.5-5 mg, 5.1-10 mg, and > 10 mg).
RESULTS: The median estimated dose ingested was 5 mg (range 0.25-200 mg). Clinically important responses developed in 27 patients (3.98%), and the prevalence of such response significantly increased from 0% for the lowest to 11.1% for the highest dose interval (p = 0.001). The smallest dose to produce a clinically important response was 2.5 mg (0.15 mg/kg). Children who ingested > 10 mg were 4.4 times more likely to develop clinically important responses than those ingesting < or = 5 mg.
CONCLUSION: Hypotension may occur in children with amlodipine doses as low as 2.5 mg. The National Poison Data System might provide useful insights regarding dose-response. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19535212     DOI: 10.1016/j.jemermed.2009.02.016

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  8 in total

Review 1.  Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies.

Authors:  Andis Graudins; Hwee Min Lee; Dino Druda
Journal:  Br J Clin Pharmacol       Date:  2015-10-30       Impact factor: 4.335

Review 2.  Amlodipine fatality in an infant with postmortem blood levels.

Authors:  Henry A Spiller; Beth A Milliner; George M Bosse
Journal:  J Med Toxicol       Date:  2012-06

3.  Near fatal case of amlodipine poisoning in an infant.

Authors:  Somashekhar M Nimbalkar; Dipen Vasudev Patel
Journal:  Indian J Pediatr       Date:  2012-07-25       Impact factor: 1.967

Review 4.  Management of Calcium Channel Blocker Toxicity in the Pediatric Patient.

Authors:  Jenna W Bartlett; Pamela L Walker
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Sep-Oct

5.  Single-Pass Albumin Dialysis as Rescue Therapy for Pediatric Calcium Channel Blocker Overdose.

Authors:  Jenna Essink; Sydney Berg; Jaka Montange; Andrew Sankey; Veronica Taylor; Jeffrey Salomon
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec

Review 6.  Calcium Channel Blocker Toxicity: A Practical Approach.

Authors:  Omar A Alshaya; Arwa Alhamed; Sara Althewaibi; Lolwa Fetyani; Shaden Alshehri; Fai Alnashmi; Shmeylan Alharbi; Mohammed Alrashed; Saleh F Alqifari; Abdulrahman I Alshaya
Journal:  J Multidiscip Healthc       Date:  2022-08-30

7.  Outcomes following calcium channel blocker exposures reported to a poison information center.

Authors:  Mikkel B Christensen; Kasper M Petersen; Søren Bøgevig; Salam Al-Gibouri; Espen Jimenez-Solem; Kim P Dalhoff; Tonny S Petersen; Jon T Andersen
Journal:  BMC Pharmacol Toxicol       Date:  2018-11-27       Impact factor: 2.483

Review 8.  Antihypertensive agents: a long way to safe drug prescribing in children.

Authors:  Nida Siddiqi; Ibrahim F Shatat
Journal:  Pediatr Nephrol       Date:  2019-11-01       Impact factor: 3.651

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.